Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Candeloro, Matteo
  • Valeriani, Emanuele
  • Monreal, Manuel
  • Ageno, Walter
  • Riva, Nicoletta
  • Peris, Maria Luisa
  • Beyer Westendorf, Jan
  • Schulman, Sam
  • Rosa, Vladimir
  • López-Núñez JJ
  • Garcia-Pagan, Juan-Carlos
  • Magaz, Marta
  • Senzolo, Marco
  • De Gottardi, Andrea
  • Di Nisio, Marcello

Grupos

Abstract

Robust evidence on the optimal management of splanchnic vein thrombosis (SVT) is lacking. We conducted an individual patient meta-analysis to evaluate the effectiveness and safety of anticoagulation for splanchnic vein thrombosis (SVT). MEDLINE, EMBASE, and clincaltrials.gov., were searched up to June 2021 for prospective cohorts or randomized clinical trials including patients with SVT. Data from individual datasets were merged, and any discrepancy with published data was resolved by contacting study authors. Three studies for a total of 1635 patients were included. Eighty-five percent of patients received anticoagulation for a median duration of 316 days (range 1 to 730 days). Overall, incidence rates for recurrent VTE, major bleeding, and mortality were 5.3/100 patients-years (p-y) (95% CI, 5.1 to 5.5), 4.4/100 p-y (95% CI, 4.2 to 4.6), and 13.0/100 p-y (95% CI, 12.4 to 13.6), respectively. The incidence rates of all outcomes were lower during anticoagulation and higher after treatment discontinuation or when anticoagulation was not administered. In multivariable analysis, anticoagulant treatment appeared to be associated with a lower risk of recurrent VTE (Hazard Ratio [HR] 0.42; 95% CI, 0.27 to 0.64), major bleeding (HR 0.47; 95% CI, 0.30 to 0.74), and mortality (HR 0.23; 95% CI, 0.17 to 0.31). Results were consistent in patients with cirrhosis, solid cancer, myeloproliferative neoplasms, unprovoked SVT, and SVT associated with transient or persistent non-malignant risk factors. In patients with SVT the risk of recurrent VTE and major bleeding is substantial. Anticoagulant treatment is associated with reduced risk of both outcomes.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Datos de la publicación

ISSN/ISSNe:
2473-9529, 2473-9537

Blood Advances  ELSEVIER

Tipo:
Article
Páginas:
4516-4523
PubMed:
35613465
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,795 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 34

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • VASCULAR DISORDERS; RISK; EFFICACY; OUTCOMES

Campos de Estudio

Cita

Compartir